OBJECTIVE: Genetic variation at the insulin-like binding protein 2 (IGF2BP2) gene has been associated with type 2 diabetes (T2D) by genome-wide association studies and by replication analyses. Our aim was to explore the underlying genetic model and mechanism of action, factors accounting for non-replications of the associations, and the effect of variation from pathway-related genes IGF2BP1 and IGF2BP3. METHOD: We analysed here the association between T2D (and related traits) and rs4402960 and rs1470579 in IGF2BP2, and rs46522 and rs6949019 (marking IGF2BP1 and IGF2BP3 respectively) from the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study (N approximately 2500 aged 65-96 years). We undertook a retrospective analysis of the deviations from the multiplicative model in previous studies and the present study. RESULTS: We replicated an association between rs4402960 and T2D status, and reported significant associations with anthropometric traits, fasting insulin, HOMA-IR and HOMA-%B. These associations were also observed for rs1470579, but not for the SNPs marking IGF2BP1 and IGF2BP3. CONCLUSIONS: The lower fasting insulin levels and the impaired beta-cell function associated with IGF2BP2 SNPs are independent of obesity phenotypes. The action of these SNPs on T2D may result from an effect on beta-cell function. This could lead to lower insulin levels, the association with anthropometric traits being secondary. We discuss possible mechanisms of action relating IGF2BP2 with T2D traits. The occurrence of null alleles, the inclusion of T2D patients in analyses of metabolic syndrome risk traits and the genetic model, are possible factors accounting for non-replications of IGF2BP2 associations with T2D. Copyright 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.
OBJECTIVE: Genetic variation at the insulin-like binding protein 2 (IGF2BP2) gene has been associated with type 2 diabetes (T2D) by genome-wide association studies and by replication analyses. Our aim was to explore the underlying genetic model and mechanism of action, factors accounting for non-replications of the associations, and the effect of variation from pathway-related genes IGF2BP1 and IGF2BP3. METHOD: We analysed here the association between T2D (and related traits) and rs4402960 and rs1470579 in IGF2BP2, and rs46522 and rs6949019 (marking IGF2BP1 and IGF2BP3 respectively) from the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study (N approximately 2500 aged 65-96 years). We undertook a retrospective analysis of the deviations from the multiplicative model in previous studies and the present study. RESULTS: We replicated an association between rs4402960 and T2D status, and reported significant associations with anthropometric traits, fasting insulin, HOMA-IR and HOMA-%B. These associations were also observed for rs1470579, but not for the SNPs marking IGF2BP1 and IGF2BP3. CONCLUSIONS: The lower fasting insulin levels and the impaired beta-cell function associated with IGF2BP2 SNPs are independent of obesity phenotypes. The action of these SNPs on T2D may result from an effect on beta-cell function. This could lead to lower insulin levels, the association with anthropometric traits being secondary. We discuss possible mechanisms of action relating IGF2BP2 with T2D traits. The occurrence of null alleles, the inclusion of T2D patients in analyses of metabolic syndrome risk traits and the genetic model, are possible factors accounting for non-replications of IGF2BP2 associations with T2D. Copyright 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.
Authors: M Sjögren; V Lyssenko; A Jonsson; G Berglund; P Nilsson; L Groop; M Orho-Melander Journal: Diabetologia Date: 2008-10-14 Impact factor: 10.122
Authors: Isabelle Cleynen; Jan R Brants; Kristel Peeters; Rob Deckers; Maria Debiec-Rychter; Raf Sciot; Wim J M Van de Ven; Marleen M R Petit Journal: Mol Cancer Res Date: 2007-04 Impact factor: 5.852
Authors: Valeriya Lyssenko; Anna Jonsson; Peter Almgren; Nicoló Pulizzi; Bo Isomaa; Tiinamaija Tuomi; Göran Berglund; David Altshuler; Peter Nilsson; Leif Groop Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Nicholette D Palmer; Mark O Goodarzi; Carl D Langefeld; Julie Ziegler; Jill M Norris; Steven M Haffner; Michael Bryer-Ash; Richard N Bergman; Lynne E Wagenknecht; Kent D Taylor; Jerome I Rotter; Donald W Bowden Journal: Diabetes Date: 2008-02-05 Impact factor: 9.461
Authors: Rong Rong; Robert L Hanson; Daniel Ortiz; Christopher Wiedrich; Sayuko Kobes; William C Knowler; Clifton Bogardus; Leslie J Baier Journal: Diabetes Date: 2008-11-13 Impact factor: 9.461
Authors: Allan F Moore; Kathleen A Jablonski; Jarred B McAteer; Richa Saxena; Toni I Pollin; Paul W Franks; Robert L Hanson; Alan R Shuldiner; William C Knowler; David Altshuler; Jose C Florez Journal: Diabetes Date: 2008-06-10 Impact factor: 9.461
Authors: Dimitry A Chistiakov; Alexey G Nikitin; Svetlana A Smetanina; Larisa N Bel'chikova; Lyudmila A Suplotova; Marina V Shestakova; Valery V Nosikov Journal: Rev Diabet Stud Date: 2012-11-15
Authors: Muhua Yang; Christina Gallo-Ebert; Michael Hayward; Weidong Liu; Virginia McDonough; Joseph T Nickels Journal: Mol Cell Biol Date: 2020-07-29 Impact factor: 4.272
Authors: Ping Rao; Hao Wang; Honghong Fang; Qing Gao; Jie Zhang; Manshu Song; Yong Zhou; Youxin Wang; Wei Wang Journal: Int J Environ Res Public Health Date: 2016-06-09 Impact factor: 3.390